Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Landos Biopharma Inc (LABP)

Landos Biopharma Inc (LABP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 71,674
  • Shares Outstanding, K 3,126
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,940 K
  • EBIT $ -26 M
  • EBITDA $ -26 M
  • 60-Month Beta 0.14
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.09
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.99
  • Most Recent Earnings $-1.43 on 05/09/24
  • Next Earnings Date 05/10/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.88
  • Number of Estimates 2
  • High Estimate -0.63
  • Low Estimate -1.12
  • Prior Year -0.63
  • Growth Rate Est. (year over year) -39.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.91 +4.66%
on 05/02/24
22.94 -0.04%
on 05/23/24
+0.78 (+3.52%)
since 04/23/24
3-Month
5.57 +311.67%
on 03/11/24
22.94 -0.04%
on 05/23/24
+16.64 (+264.55%)
since 02/23/24
52-Week
2.50 +817.20%
on 06/01/23
22.94 -0.04%
on 05/23/24
+19.64 (+596.96%)
since 05/23/23

Most Recent Stories

More News
Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update

Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range of...

LABP : 22.93 (+0.58%)
Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update

Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year ...

LABP : 22.93 (+0.58%)
Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical...

LABP : 22.93 (+0.58%)
Landos Biopharma Announces Leadership Transition

Josep Bassaganya-Riera Steps Down as Chairman, President and CEO Tim M. Mayleben Appointed Interim President and CEO Chris Garabedian Appointed...

LABP : 22.93 (+0.58%)
Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid Arthritis

Phase 1 trial is underway with topline results expected in the first half of 2022 Represents Landos’ seventh IND cleared overall and the second IND...

LABP : 22.93 (+0.58%)
Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus

Phase 1 trial initiation expected before yearend with topline results in 1H 2022 BLACKSBURG, Va., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma,...

LABP : 22.93 (+0.58%)
Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancor’s Therapeutic Potential in Models of Psoriasis and Further Validating the LANCL2 Mechanism

BLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its...

LABP : 22.93 (+0.58%)
Landos Biopharma to Participate in Truist Securities CEO Fireside Chat Series (Virtual)

BLACKSBURG, Va., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE ® advanced A.I. platform to develop novel...

LABP : 22.93 (+0.58%)
Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohn’s Disease with the Icahn School of Medicine at Mount Sinai

Second Phase 2 trial of omilancor in Crohn’s disease (CD), expected to initiate in 2021

LABP : 22.93 (+0.58%)
Landos Biopharma to Present Results of LABP-104 in Lupus at the American College of Rheumatology Convergence 2021

Oral treatment with LABP-104 in preclinical models of Systemic Lupus Erythematosus (SLE) resulted in enhanced Treg function, decreased kidney inflammation and reduced interferon gamma signaling

LABP : 22.93 (+0.58%)

Business Summary

Landos Biopharma Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. Landos Biopharma Inc. is based in BLACKSBURG, Va.

See More

Key Turning Points

3rd Resistance Point 23.19
2nd Resistance Point 23.06
1st Resistance Point 23.00
Last Price 22.93
1st Support Level 22.81
2nd Support Level 22.68
3rd Support Level 22.62

See More

52-Week High 22.94
Last Price 22.93
Fibonacci 61.8% 15.13
Fibonacci 50% 12.72
Fibonacci 38.2% 10.31
52-Week Low 2.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar